December 8, 2025BloodOpen Access

Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy

View Full Paper

Ask AI

Bookmark

ctDNA monitoring improves prognostic assessments for large B-cell lymphoma patients receiving car T-cell therapy, enhancing prediction accuracy.
In a cohort study, undetectable ctDNA at key timepoints was significantly associated with improved progression-free survival metrics.
The approach involved comprehensive plasma collection and monitoring using clonoSEQ in patients treated with axi-cel or liso-cel.
Integration of ctDNA may reduce the need for routine PET-CT imaging, offering a more dynamic tracking option for early relapse detection.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational analysis shows ctDNA monitoring enhances prognostic value in CAR T-cell therapy for large B-cell lymphoma, implying reduced reliance on PET-CT scans.

Cite This Study

Ananth et al. (2025) studied this question.

synapsesocial.com/papers/69362f604fa91c937236dcad https://doi.org/10.1182/blood-2025-941

View Full Paper

Ask AI

Bookmark

Implication

Observational analysis shows ctDNA monitoring enhances prognostic value in CAR T-cell therapy for large B-cell lymphoma, implying reduced reliance on PET-CT scans.

Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy

Key Points

Discussion

Implication

Cite This Study

Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider